Please select the eligibility criteria that correspond to the clinical trial below.
Title: Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)
Brief Summary: This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.


Options:
A: Inclusion Criteria:

* Mean sitting sBP and dBP prior to randomization of 140-180/90-105 mmHg
* Increased cardiovascular risk, e.g.: a) documented or clinical signs of peripheral atherosclerotic disease stage IIa or lower; b) diabetes mellitus type 2; c) left ventricular hypertrophy on echo; d) current smoking; e) old myocardial infarction, stroke or TIA
* Intima-media thickness of the common carotid artery greater than or equal to 0.8 and less than or equal to 1.6 mm (measured ultrasonographically) or the plaque volume of the carotid bulb greater than or equal to 4 μl and less than or equal to 500 μl

Exclusion Criteria:

* Body mass index \> 30
* Any type of known secondary hypertension
* Electrocardiographic evidence of 2nd or 3rd degree atrioventricular block, atrial fibrillation, cardiac arrhythmia requiring therapy or bradycardia at rest (\< 50/min)
* Obstructive pulmonary disease
* Claudicatio intermittens
* History or clinical evidence of any significant gastrointestinal, respiratory, hematological, metabolic, immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient's participation in the trial
* Hypersensitivity or contraindication to ARBs, Beta-Blockers, HCTZ or any cross allergy
* Pre-treatment with ARBs or ACE inhibitors within 6 months prior to screening
* Treatment with disallowed medication
* Pregnant or breastfeeding females or females of childbearing potential without adequate contraception
* History of alcohol and/or drug abuse
B: Men and women, aged 60 or over, with isolated systolic hypertension.
C: Inclusion Criteria:

* Patients admitted to hospital with COVID-19
* No immediate requirement for mechanical ventilation (points 3-5 on the WHO ordinal scale)
* Age equal to or greater than 18
* Able to provide informed consent

Exclusion Criteria:

* Pregnant women
* Known allergy to Heparin
* Participant in another clinical trial that is not approved for joint enrollment.
* APTT\> 120 seconds, not due to anticoagulant therapy.
* Platelet count \<20 x 109 per L
* Lung bleeding.
* Uncontrolled bleeding
* Advanced neurological impairment
* Advanced oncological disease
D: Inclusion Criteria:

* Hospitalized, COVID-19 positive, between 18 and ≤ 85 years of age;
* Signed Inform Consent Form;
* Body temperature \> 37.3 ℃;
* Oxygenation criterion (any of the following): i) Oxygen saturation ≤94% on Room Air; ii) PaO2/FiO2 ratio ≤300 mmHg but \> 100 mmHg, if patient on supplemental oxygen; iii) SpO2/FiO2\<200 if no arterial blood gas available;
* Respiratory rate (RR) ≥ 25 beats/min.

Exclusion Criteria:

* Pregnant or lactating females;
* Unwillingness or inability to complete the study.
* Rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator;
* eGFR \< 30 ml/min/m2 assessed with CKD EPI formula;
* Current or chronic history of liver disease (Child Pugh score ≥ 10), or known hepatic or biliary abnormalities;
* Participation in a clinical trial with an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer);
* Patients requiring high doses of loop diuretics (i.e. \> 240 mg furosemide daily) with significant intravascular volume depletion, as assessed clinically;
* History of allergy;
* History of sensitivity to heparin or heparin-induced thrombocytopenia;
* Unstable hemodynamics in the preceding 4 hours (SBP \< 90 mmHg, and/or vasoactive agents required);
* Hemoglobin \< 7 at time of drug infusion. Transfusion is allowed to increase hemoglobin levels before entry into the study;
* Malignancy or any other condition for which estimated 6-month mortality \>50%;
* Arterial blood pH less than 7.2;
* Known evidence of chronic interstitial infiltration at imaging;
* Known hospitalization within the past six months for respiratory failure (PaCO2 \> 50 mmHg or PaO2 \< 55 mmHg, or oxygen saturation \<88% on FiO2 = 0.21);
* Known chronic vascular disease resulting in severe exercise restriction (i.e. unable to perform household duties);
* Known secondary polycythemia, severe pulmonary hypertension, or ventilator dependency;
* Known vasculitis with diffuse alveolar hemorrhage;.
* Pre-existing renal failure on hemodialysis or peritoneal dialysis requiring renal replacement therapy;
* Extracorporeal membrane oxygenation (ECMO);
* Immunosuppressive treatment;
* Patient in trials for COVID-19 within 30 days before;
* Unstable hemodynamics in the preceding 4 hours (MAP ≤ 65 mmHg, or SAP \< 90 mmHg, DAP \< 60 mmHg, and vasoactive agents required);
* Hyperkalemia , i.e. serum K+ levels \> 5.0 mEq/L;
* Severe active bleeding;
* Any other uncontrolled comorbidities that increase the risks associated with the study drug administration, as assessed by the medical expert team.

Answer: A